AI Summary
We reviewed 12 live results for rituximab and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Comparison Table
Recommended
Truxima (rituximab-abbs)
Source: Teva Pharmaceuticals
Description
Truxima (rituximab-abbs) is a CD20-directed cytolytic antibody and was the first FDA-approved biosimilar to Rituxan. It is indicated for adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) in combination with methotrexate, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV). The medication is administered as an intravenous (IV) infusion by healthcare professionals and is available in 100 mg/10 mL and 500 mg/50 mL single-dose vials. Teva provides a cost support program for eligible commercially insured patients.
Best for
Adults with Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia treatment, Moderate-to-severe Rheumatoid Arthritis, Patients seeking Rituxan biosimilars and Intravenous infusion therapy
View Details
Rating
Ruxience (rituximab-pvvr)
Source: Pfizer Inc.
Description
Ruxience is a biosimilar to the reference product Rituxan (rituximab). It is a prescription biological medicine used for the treatment of adults with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). Administered via intravenous infusion, it is available in 100 mg/10 mL or 500 mg/50 mL single-dose vials. As a monoclonal antibody, it works by targeting the CD20 antigen on the surface of B-cells, facilitating their destruction by the immune system.
Best for
oncology patients, rheumatoid arthritis management, biosimilar therapeutic options and hematologic malignancies
View Details
Rating
Truxima (Rituximab)
Source: Celltrion Healthcare Philippines Inc.
Description
Truxima is the first oncology monoclonal antibody biosimilar in the Philippines, listed in the Philippine National Formulary for cancer treatment.
Best for
oncology patients, monoclonal antibody therapy and formulary-listed treatments
View Details
Rating
| Compare | Truxima (rituximab-abbs) | Ruxience (rituximab-pvvr) | Truxima (Rituximab) |
|---|---|---|---|
| Source | Teva Pharmaceuticals | Pfizer Inc. | Celltrion Healthcare Philippines Inc. |
| Description | Truxima (rituximab-abbs) is a CD20-directed cytolytic antibody and was the first FDA-approved biosimilar to Rituxan. It is indicated for adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) in combination with methotrexate, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV). The medication is administered as an intravenous (IV) infusion by healthcare professionals and is available in 100 mg/10 mL and 500 mg/50 mL single-dose vials. Teva provides a cost support program for eligible commercially insured patients. | Ruxience is a biosimilar to the reference product Rituxan (rituximab). It is a prescription biological medicine used for the treatment of adults with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). Administered via intravenous infusion, it is available in 100 mg/10 mL or 500 mg/50 mL single-dose vials. As a monoclonal antibody, it works by targeting the CD20 antigen on the surface of B-cells, facilitating their destruction by the immune system. | Truxima is the first oncology monoclonal antibody biosimilar in the Philippines, listed in the Philippine National Formulary for cancer treatment. |
| Best for | Adults with Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia treatment, Moderate-to-severe Rheumatoid Arthritis, Patients seeking Rituxan biosimilars and Intravenous infusion therapy | oncology patients, rheumatoid arthritis management, biosimilar therapeutic options and hematologic malignancies | oncology patients, monoclonal antibody therapy and formulary-listed treatments |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Truxima (rituximab-abbs) from Teva Pharmaceuticals."
I picked this because Truxima is a significant clinical option as the first FDA-approved biosimilar to Rituxan, offering a high-quality, clinically equivalent alternative for treating B-cell malignancies and autoimmune diseases.
Share this search
Related Finds